• Explore /
  • Poster
  • / Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC).

Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC).

Abstract Poster

Authors

null

Hyo S. Han

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Hyo S. Han , Ricardo L Costa , Hatem Hussein Soliman , Aixa Soyano , Hung T. Khong , Loretta S. Loftus , Kimberley T Lee , Avan J. Armaghani , Hien Liu , Jessica Malka , Frederick L. Locke , Qianxing Mo , Junmin Whiting , Lavakumar Karyampudi , Elizabeth E. Evans , Terrence Lee Fisher , Maurice Zauderer , Brian J. Czerniecki

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT05378464

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS1113)

DOI

10.1200/JCO.2023.41.16_suppl.TPS1113

Abstract #

TPS1113

Poster Bd #

333a

Abstract Disclosures

Similar Posters

First Author: Stephen K. L. Chia

First Author: D. Gajria

First Author: Nicholas Patrick McAndrew

First Author: Martin Gutierrez